Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lacidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lacidipine SCHEMBL49278 | 1.00 | CYP2C9 (1.00) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| Lacidipine SCHEMBL29352892 | 1.00 | CYP2C9 (1.00) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| Lacidipine SCHEMBL28158205 | 0.98 | CYP2C9 (0.96) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL29262164 | 0.96 | ADORA3 (0.92) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL29261988 | 0.96 | ADORA3 (0.92) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL29285310 | 0.96 | ADORA3 (0.92) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL9680055 | 0.92 | SLC6A2 (0.85) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL9680051 | 0.92 | SLC6A2 (0.85) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| Bromide SCHEMBL9679913 | 0.91 | SLC6A2 (0.83) | CYP2C9ADORA3LMNACYP3A4CYP2C19 | |
| SCHEMBL5468704 | 0.91 | ADORA3 (0.83) | CYP2C9ADORA3LMNACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10246 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107412-A1 | SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-119901725-B | Rapid detection method for raschidine and fluvoxamine in serum at accident site | 中国人民解放军空军特色医学中心 | 2025-05-30 | — | — | CN | claimed |
| CN-119936406-A | Sodium overload cell death pathway and uses thereof | 上海交通大学医学院 | 2025-05-06 | — | — | CN | claimed |
| CN-119901725-A | Rapid detection method for raschidine and fluvoxamine in serum at accident site | 中国人民解放军空军特色医学中心 | 2025-04-29 | — | — | CN | claimed |
| EP-0557244-A1 | Dosage forms having prolonged active-ingredient release | Siegfried Pharma AG (CH) | 1993-08-25 | — | — | EP | claimed |
| EP-0550446-A1 | RADIOPROTECTION BY CALCIUM ANTAGONISTS | BAYER AG (DE) | 1993-07-14 | — | — | EP | claimed |
| CN-1070907-A | Preparation 4-replaces-1, the novel method of 4-dihydropyridine | MERCK & CO INC (US) | 1993-04-14 | — | — | CN | claimed |
| WO-1993006082-A1 | PROCESS FOR THE PREPARATION OF 4-SUBSTITUTED-1,4-DIHYDROPYRIDINES | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0534520-A2 | Process for the preparation of 4-substituted-1,4-dihydropyridines | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1993002670-A1 | RADIOPROTECTION BY CALCIUM ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-02-18 | — | — | WO | claimed |
| EP-0397413-A1 | Improved particle gun | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 1990-11-14 | — | — | EP | claimed |
| EP-0370974-A2 | Process for preparing heterocyclic derivatives | GLAXO S.p.A. (IT) | 1990-05-30 | — | — | EP | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| US-4801599-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS | GLAXO S.P.A. (IT) | 1989-01-31 | — | — | US | claimed |